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From an architectural point of view, the forebrain acts as a framework upon which the middle and upper face develops and grows. In
addition to serving a structural role, we present evidence that the forebrain is a source of signals that shape the facial skeleton. In this
study, we inhibited Sonic hedgehog (Shh) signaling from the neuroectoderm then examined the molecular changes and the skeletal
alterations resulting from the treatment. One of the first changes we noted was that the dorsoventral polarity of the forebrain was
disturbed, which manifested as a loss of Shh in the ventral telencephalon, a reduction in expression of the ventral markers Nkx2.1 and
Dlx2, and a concomitant expansion of the dorsal marker Pax6. In addition to changes in the forebrain neuroectoderm, we observed altered
gene expression patterns in the facial ectoderm. For example, Shh was not induced in the frontonasal ectoderm, and Ptc and Gli1 were
reduced in both the ectoderm and adjacent mesenchyme. As a consequence, a signaling center in the frontonasal prominence was
disrupted and the prominence failed to undergo proximodistal and mediolateral expansion. After 15 days of development, the upper beaks
of the treated embryos were truncated, and the skeletal elements were located in more medial and proximal locations in relation to the
skeletal elements of the lower jaw elements. These data indicate that a role of Shh in the forebrain is to regulate Shh expression in the
face, and that together, these Shh domains mediate patterning within the frontonasal prominence and proximodistal outgrowth of the
middle and upper face.
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Introduction epithelium influences the patterning and growth of theThe facial skeleton is an agglomeration of bones and
cartilages that arise from distinct facial prominences, each of
which is unique in terms of the epithelia that surround them
and the rostrocaudal origins of the neural crest which
comprise the skeletogenic mesenchyme (Couly and Le
Douarin, 1990; Thorogood, 1988, 1993). The mandibular
prominence gives rise to the lower jaw skeleton, and studies
in a variety of animal models indicate that the pharyngeal0012-1606/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to the work.mandibular skeleton (Couly et al., 2002; Kimmel et al.,
2001; Miller et al., 2000). The maxillary and lateral nasal
prominences give rise to lateral parts of the upper jaw
skeleton, and epithelial–mesenchymal interactions are also
important for their proper morphogenesis (Depew et al.,
2002; Ozeki et al., 2004). The central portion of the upper
jaw skeleton is derived from the frontonasal prominence,
and in this structure, the frontonasal epithelium is required
for morphogenesis (Hu et al., 2003).
The forebrain neuroectoderm also participates in cranio-
facial patterning, but in ways that are not clearly defined. The
forebrain acts as a structural support for facial development,
as exemplified by the clinical condition of holoprosencephaly
(HPE) (Cohen and Sulik, 1992; Muenke, 1994; Muenke and284 (2005) 48 – 61
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typically results in alterations of facial elements derived from
the frontonasal prominence. Likewise, craniofacial defects
arising as a result of disruptions in the activity of growth
factors that are required by the neuroectoderm, such as
retinoids (Niederreither et al., 1999) and fibroblast growth
factors (Creuzet et al., 2004), may be attributable to a collapse
of the forebrain scaffold, due to apoptosis in this tissue layer
(Creuzet et al., 2004; Schneider et al., 2001).
Facial malformations may also arise because signals
emanating from the forebrain provide instructional informa-
tion to the tissues of the face. If such a scenario were true, then
the loss of forebrain signals would compromise normal facial
development, despite an intact supporting framework. To
explore whether the forebrain acted as more than supporting
framework for facial morphogenesis, we examined how
Sonic hedgehog (Shh), which has a well-documented role in
forebrain development (Chiang et al., 1996; Ericson et al.,
1995a; Macdonald et al., 1995; Ye et al., 1998), affects
craniofacial development. Shh is produced by multiple
epithelia in the head, including forebrain neuroectoderm
(Echelard et al., 1993), frontonasal and maxillary ectoderm
(Helms et al., 1997), and pharyngeal endoderm (Bitgood and
McMahon, 1995). Disruptions in Shh signaling, or an
inability of neural crest cells to respond to Hedgehog
signaling, results in a range of craniofacial dysmorphologies.
Most of these experimental approaches either eliminated an
entire tissue (Hu and Helms, 1999), inhibited the ability of
Shh to bind to its receptor (Ahlgren and Bronner-Fraser,
1999; Cordero et al., 2004; Hu and Helms, 1999), eliminated
Shh from all tissues (Chiang et al., 1996), or eliminated the
ability of specific tissues to respond to Shh (Jeong et al.,
2004). We wanted to discriminate the function of Shh in the
forebrain neuroectoderm from its role in the other head
epithelia, and to pinpoint which aspect of craniofacial
morphogenesis was regulated by this particular source of
Shh. We used an experimental approach that allowed us to
selectively disrupt Shh signaling originating from the
forebrain neuroectoderm and examined the morphological,
cellular, and molecular consequences of this perturbation on
forebrain and facial patterning, on craniofacial morphogen-
esis, and on development and maturation of the craniofacial
skeleton. In doing so, we uncovered a Shh-dependent
signaling center within the forebrain that regulates Shh
expression in the face. Furthermore, we show that Shh
signaling within the forebrain is not required for the initiation
of skeletogenesis, but rather for elaborating the proximodistal
andmediolateral axes of the middle and upper facial skeleton.Materials and methods
In situ hybridization and immunohistochemistry
Patterns of gene expression were analyzed by in situ
hybridization using radiolabeled riboprobes as previouslydescribed (Albrecht et al., 1997). Subclones of Shh, Ptc1,
Gli1, Fgf8, Pax6, Otx2, Dlx2, Nkx2.1, AP2, Msx1, and
BarX1 were linearized to transcribe 35S- or DIG-labeled
riboprobes. Images of radioactive in situ hybridization
assays are pseudo-colored superimpositions of the in situ
hybridization signal and a blue nuclear stain (Hoescht Stain,
Sigma) that are made using Adobe Photoshop. Briefly, two
separate images were captured in Adobe Photoshop. One
image was a fluorescent image of the nuclei, and the other
was a dark field image of the in situ hybridization signal.
These images were then superimposed as different layers
within Photoshop. The ‘‘colorize’’ tool was used to add a
contrasting color to everything within the layer containing
the in situ hybridization signal. No changes in threshold
intensities were made; however, slight adjustments to the
contrast and brightness were performed to accurately reflect
what was observed with the microscope. The image was
then flattened for importation into Adobe Illustrator, where
the final figures were assembled.
The detection of the 5E1 and 40-1A antibodies was
accomplished on sections that were adjacent to those used
for in situ hybridization. De-paraffinized, rehydrated sec-
tions were incubated for 10 min at room temperature in 3%
H2O2 to quench endogenous peroxidase activity and then
washed 3 times in wash buffer (PBS supplemented with 3
mg/ml BSA and IGEPAL detergent (0.1%)). Anti-mouse
IgG conjugated to horse-radish peroxidase ((HRP) diluted
1:200) was applied to sections in wash buffer containing
10% normal goat serum and incubated overnight at 4-C.
Sections were washed 3 times in wash buffer followed by a
final wash in PBS. HRP was visualized by the application of
diaminobenzidine supplemented with nickel and cobalt. The
sections were counterstained with eosin and cover-slipped
before viewing on a Leica DMRB brightfield microscope.
Preparation of embryos and inhibition of Shh signaling in
the neuroectoderm
Fertilized chicken eggs (Gallus gallus, Rhode Island Red
Chickens from Petaluma Farms, Petaluma, CA) were
prepared for surgical manipulations as follows. A small
hole was made in the shell directly over the embryo after
removing 1.0 ml of albumin, and embryos were visualized
by applying neutral red (Gibco, diluted 1:20 in Hanks
Balanced Salt Solution, Sigma) using a blunt glass rod. To
gain access to the embryo, the entire vitelline membrane
was removed from over the embryo.
The inhibition of Shh signaling originating within the
neuroectoderm was achieved by injecting hybridoma cells
that expressed either the immunoneutralizing anti-Shh
antibody (i.e., 5E1; Ericson et al., 1995b), or the control,
anti-h-galactosidase antibody (i.e., 40-1A). Approximately
0.15 Al of media containing Trypan blue and cells (40  106
cells/ml) was injected into the anterior neural tube of stage
10 (Hamburger and Hamilton, 1951) chicken embryos. Both
antibodies are IgG1 isotypes (Developmental Studies
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maldehyde (PFA) for 2 h at room temperature or overnight
at 4-C and then dehydrated through a graded ethanol series
and stored in 100% ethanol at 20-C until analysis.
Molecular, cellular, and histological analyses (detailed
below) were performed on treated and control embryos that
developed for an additional 0.5, 1, 2, 4, and 5 days. The
craniofacial skeleton was examined at St. 36 and 40 using
whole-mount staining with Alizarin Red and Alcian Blue,
followed by clearing in a graded series of glycerol
(Wassersug, 1976).
Neural crest ablation and labeling of the neural tube
Sharpened tungsten needles were used to excise the
anterior neural folds of embryos at St. 8 or St. 9. The entire
dorsal surface of the pros- and mesencephalon was removed
and the embryos were allowed to develop to St. 18, 20, or
22. After removal of the neural crest progenitors a small
portion of the cut edge of the neural tube was labeled with
carboxyfluorescein diacetate (CFSE, Molecular Probes)
because it easily permeates cell membranes and becomes
fluorescent once it is in the cytoplasm of cells. The embryos
were collected, fixed in 4% PFA, and processed for analysis
of gene expression patterns and immunohistochemistry as
previously described (Fernandez-Garre et al., 2002).
Programmed cell death and cell proliferation
At 24 and 48 h after injection of 5E1 or 401A cells, or at
the equivalent time for untreated embryos, and at St. 20 and
St. 25, programmed cell death was determined in every fifth
section using the In situ Cell Death Detection Kit
(Boehringer Mannheim). Briefly, terminal transferase was
used to incorporate fluorescein-dUTP directly into strand
breaks. The incorporated fluorescein was visualized using
epifluorescent illumination and a Leica DMRB microscope.
Twenty minutes prior to fixation, BrDU (Zymed) was
injected into the vitelline vein of embryos. Incorporated
BrDU was visualized and analyzed as previously described
(Hu and Helms, 1999). Images of stained sections were
obtained from 5 treated and 4 control embryos at St. 20. The
proportion of BrDU-positive cells were determined in four
sections from each embryo and averaged. Averaged
measures were subjected to a two-tailed t test to determine
whether statistically significant differences in proliferation
rates resulted from our treatment.
Replacement of Shh or Fgf8 after 5E1 treatment
Affi-Gel Blue beads (50–100 mesh, 200–250 Am
diameter; Biorad) were soaked in recombinant Shh-N
protein (400 Ag/ml in PBS with 0.1% bovine serum
albumin (BSA); Ontogeny) or 0.1% BSA at 37-C for 1
h. Fgf2 protein (400 Ag/ml; R&D Systems) was incubated
for 1 h with Heparin sulfate beads (200–250 Am diameter;BioRad) at 37-C as described (Hu et al., 2003). Forty eight
hours after Shh signal inhibition (approximately St. 18–
20), Shh- or Fgf2-soaked beads were placed between the
facial ectoderm and the forebrain neuroectoderm. Embryos
were collected after an additional 24 h of incubation
(approximately St. 22), and gene expression patterns were
examined.Results
Shh is expressed in a progressive manner in the forebrain
and face
A growing literature underscores the importance of Shh
signaling in establishing patterning within the neural plate
(Gunhaga et al., 2000; Kobayashi et al., 2002; Tanabe et al.,
1995; Ye et al., 1998), but our goal was to specifically study
the role of Shh signaling from the forebrain after neurula-
tion. To do so, we injected hybridoma cells expressing an
anti-Shh immunoneutralizing antibody (5E1; Ericson et al.,
1995b) or a control antibody (anti-h-galactosidase antibody
(40-1A)) into the lumen of the forebrain. The earliest stage
after neurulation that this could be accomplished was at St.
10, since prior to this stage, the anterior neuropore is open
and the injected cells easily escape the confines of the neural
tube. After injecting the anti-Shh antibody or control
hybridoma cells at St. 10, we examined embryos at a
variety of time points. In order to better understand the
sources of Shh that would be potentially inhibited by this
treatment, we began by examining the endogenous pattern
of Shh expression in the head spanning this experimental
period.
Shh is initially expressed in the midline of the neural
plate, and by St. 9, this domain becomes the ventral
prosencephalon. At St. 9 and 10, Shh transcripts are also
detected in the prechordal plate mesoderm and the
pharyngeal endoderm (Fig. 1A). By St. 12, Shh also is
induced in the ectodermal and endodermal cells of the
buccopharyngeal membrane (Fig. 1B). After St. 12, the
prosencephalon begins to expand and becomes divided into
the diencephalon and the telencephalon. The Shh expression
domain that was observed at St. 9 persists in the ventral
diencephalon, and at St. 17, Shh is induced in the ventral
telencephalon (Fig. 1C). At St. 20, a new Shh expression
domain arises in the ectoderm covering the ventral
frontonasal prominence (Fig. 1D).
5E1 cells specifically perturbs forebrain Shh signaling
Based on these gene expression patterns, we surmised
that the 5E1-expressing cells injected into the lumen of the
neural tube (Fig. 1E) at St. 10 should disrupt Shh signaling
from the neural tube exclusively, since none of the other
Shh-expressing tissues would be in contact with the
hybridoma cells. To confirm that the Shh inhibition occurred
Fig. 1. Ontogeny of Shh expression. (A) In situ hybridization of a sagittal
section of a St. 9 embryo reveals that Shh transcripts are present in the floor
of the prosencephalon (pr, arrow), the prechordal mesoderm (asterisk), and
the pharyngeal endoderm (pe, arrowhead). (B) By St. 12, Shh transcripts are
also detected in the buccopharyngeal membrane (arrow). (C) At St. 17, two
domains of Shh expression are evident in the forebrain. The original
expression domain of Shh in the prosencephalon persists in the
diencephalon (di), and Shh expression is initiated in the telencephalon
(te, arrow). (D) At St. 20, Shh is induced in the facial ectoderm (fe, arrow)
concomitant with the arrival of neural crest cells into the frontonasal
primordium. (E) Dorsal view of the head of a St. 10 embryo. The lumen of
the neural tube was filled with hybridoma cells. Trypan blue (0.1%) was
added to the solution prior to injection. (F) Seventy-two hours after the
injection of hybridoma cells, immunoreactivity was limited to sites of Shh
expression in the neural tube (arrow) and hybridoma cells within the lumen.
No immunoreactivity was detected outside of the neural tube. or, optic
recess; ma, mandible; rp, Rathke’s pouch; me, mesencephalon; pm, paraxial
mesoderm. Scale bars: 100 Am.
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immunoreactivity was restricted to hybridoma cells residing
in the neural tube, and to the neuroectoderm that was
producing Shh (n = 12, Fig. 1F; see also Ahlgren and
Bronner-Fraser, 1999). By starting our treatment at St. 10,
we avoided disrupting the generation of neural crest cells,
which by this time point were already en route to the facial
prominences. Consequently, the molecular and morpholog-
ical changes we observed could be exclusively ascribed to
disruptions in Shh signaling in the forebrain and not to
disruptions in the production or the migration of cranial
neural crest cells, or to blockade of Shh signaling from other
sources such as the pharyngeal endoderm.
We next confirmed that 5E1 treatment specifically
disrupted Shh signaling by examining the expression of
Ptc and Gli1, two downstream targets of Shh signaling
(Dahmane et al., 1997; Goodrich and Scott, 1998; Ruiz iAltaba, 1997), in embryos at St. 22. We compared the
expression patterns of Ptc and Gli1 in control (40-1A, Figs.
2A, C) and 5E1 (Figs. 2B, D) treated embryos and found
that, in embryos treated with the anti-Shh antibody, both
target genes were down-regulated in the neuroectoderm, as
well as in the facial mesenchyme and overlying surface
ectoderm (Figs. 2B, D). Ptc expression was absent from the
telencephalon, frontonasal mesenchyme, and facial ecto-
derm (Fig. 2B), while Gli1 expression was absent from the
diencephalon, frontonasal mesenchyme, and facial ectoderm
of treated embryos (Fig. 2D). We were surprised by the lack
of Ptc and Gli1 expression within the facial ectoderm and
frontonasal process mesenchyme for two reasons. First, the
antibody was restricted to the neural tube, and hence, the
Shh signaling pathway should only be affected in this tissue.
Second, in mesenchymal and epithelial areas adjacent to
other sources of Shh (e.g., pharyngeal endoderm, chordal
mesoderm), Ptc and Gli1 expressions were maintained.
Nonetheless, the down-regulation of Ptc and Gli1 in the
frontonasal prominence was unmistakable (n = 12/12; Figs.
2A–D), and thus, we concluded that the treatment
suppressed Shh signaling in the forebrain and frontonasal
prominence.
Forebrain Shh signaling controls facial Shh expression
The induction of Shh in both the telencephalon and the
facial ectoderm was eliminated by 5E1 treatment, but other
domains of Shh (e.g., pharyngeal endodermal, diencepha-
lon, n = 6/6, Figs. 2E, F) were not affected. Therefore, Shh
signaling from the neuroectoderm, either directly or
indirectly, regulated its own expression in the telencephalon
and in the frontonasal process ectoderm. Since neural crest
cells are located between forebrain neuroectoderm and facial
ectoderm, and they express the Hedgehog receptor Ptc (Fig.
2A), we suspected that neural crest cells could act as a
conduit through which the forebrain Shh signal was
transduced. Our first strategy to test this hypothesis was to
extirpate the neural crest destined for this region of the face
and examine how this removal affected Shh expression in
facial ectoderm. At St. 8 (n = 3) or 9 (n = 7), we excised the
neural folds from the middle of the forebrain to rhombomere
2 (Figs. 3A, B), where frontonasal, maxillary, and mandib-
ular neural crest cells are generated (Couly and Douarin,
1988; Noden, 1978), and examined the embryos at various
stages for changes in patterns of gene expression. When we
examined these embryos at St. 20, we found that they were
grossly disfigured as a consequence of neural crest removal,
but we were still able to determine that the expression of
Shh in the telencephalon was not affected. However, it
appeared that Shh induction in the facial ectoderm was
altered in a proportion of the embryos (5/10, Fig. 3F). The
stage at which we performed the ablation did not appear to
influence this result. For example, two of three embryos
ablated at St. 8 lost Shh expression at St. 20, and three of
seven embryos lost Shh expression when we removed
Fig. 2. Molecular changes after the inhibition of Shh signaling. (A) In situ
hybridization performed on sagittal sections of control embryos demon-
strates that Ptc (pink) is expressed in the neuroectoderm (ne) of the
forebrain, the mesenchyme adjacent to Shh-expressing tissues, and the
facial ectoderm beneath the forebrain (arrow). (B) After the inhibition of
Shh signaling, Ptc expression is down-regulated in the neural tube, but is
still detectable in the floor of the anterior diencephalon (di). Ptc transcripts
are barely detectable in the mesenchyme surrounding the forebrain and in
the facial ectoderm beneath the forebrain (arrow). (C) In the neural tube,
Gli1 (orange) is expressed in domains adjacent to those that express Shh.
High levels of Gli1 are expressed in the optic recess (or) and in the
telencephalon (te) adjacent to the domain that expresses Shh. Gli1
transcripts are also detected in the facial ectoderm (arrow) and in the
neural crest mesenchyme between the facial ectoderm and the forebrain. (D)
After Shh signal inhibition, Gli1 expression is only observed in the
telencephalon located immediately adjacent to the optic recess. Gli1
transcripts are also reduced in the facial ectoderm (arrow) and neural crest
mesenchyme. (E) In the forebrain, two domains of Shh expression, one in
the telencephalon and one in the diencephalon, separated by the optic
recess, are present. Shh is also expressed in the facial ectoderm below the
floor of the forebrain (arrow). (F) After the inhibition of Shh within the
forebrain, Shh is only expressed in the floor of the diencephalon, but is
absent from the posterior telencephalon. Shh is not expressed in the facial
ectoderm after treatment with 5E1 (arrow). The other domains of Shh
expression within the neural tube, endoderm, and mesoderm are not
affected. (G) Whole mount in situ hybridization reveals that Fgf8
expression (arrow) spans the frontonasal process ectoderm at St. 20. (H)
In treated embryos, this expression domain (arrow) is unaltered. rp,
Rathke’s pouch; ma, mandibular arch; nc, notochord. Scale bars: A–F:
200 Am, G–H: 1 mm.
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the Fgf8 or BarX1 expression domains in either the brain or
the face at St. 20 (n = 4, Figs. 3G–J), so the loss of Shh in
facial ectoderm was not a general consequence of cell death
in this tissue.
Since the cut edges of the neural tube have been shown
to regenerate a population of neural crest cells (Couly et
al., 1996, 2002; Creuzet et al., 2004), we wondered
whether embryos allowed to develop for longer periods
would begin to express Shh in the facial ectoderm.
Embryos developing to St. 22 had severe facial malforma-
tions, but because structures normally derived from neural
crest cells were still present (Fig. 3K), and because
mesenchymal cells were evident in the frontonasal
prominence (Fig. 3L), we concluded that the neural crest
population had begun to regenerate. In the majority (n = 3/4)
of these embryos, Shh was expressed in the facial ectoderm
(Fig. 3L).
To determine whether the mesenchymal cells that we
observed had regenerated from the neural tube, we
repeated the extirpation experiment and applied a small
amount of the lipophilic dye, CFSE, to a localized area of
the cut edge of the neural tube. Embryos developed until
St. 18 (n = 7) or 20 (n = 7), after which time the presence
of labeled cells and Shh expression were assessed. In order
to restrict CFSE labeling to cells regenerated from the
neuroepithelium, only a small amount of CFSE was
applied to prevent contaminating adjacent tissues with
CFSE and thereby rendering our results invalid. We
discovered that when Shh transcripts were detectable in
the ectoderm (7/7, Fig. 3M), labeled cells were also
present within the mesenchyme of the frontonasal process
of embryos at St. 20 (Fig. 3N). When embryos were
examined earlier, at St. 18, Shh expression was restricted
to lateral domains in the ectoderm of the frontonasal
process (7/7, Fig. 3O). Further, no mesenchymal cells had
migrated as far as the midline of the frontonasal
prominence, and the labeled cells were restricted to lateral
regions of mesenchyme (Fig. 3P). Taken together, these
data show a correlation between the presence of neural
crest cells in the frontonasal prominence and the induction
of Shh in facial ectoderm. Thus, we conclude that neural
crest cells appear to act as a conduit through which a Shh-
dependent signal from the forebrain neuroectoderm induces
Shh expression in frontonasal ectoderm. Experimental
variability is, however, a hallmark of extirpation experi-
ments, so we took a different tactic to address whether Shh
directly or indirectly induced its own expression in facial
ectoderm.
In our next experiment, we blocked the endogenous
source of Shh in the forebrain then provided an exogenous
source of Shh in proximity to the region where Shh was
normally expressed. Our idea was to remove the endoge-
nous domain of Shh in the forebrain by treatment with the
5E1 cells and substitute an ectopic source of the same signal
into the mesenchyme, in order to test if Shh protein could
Fig. 3. Neural crest cells are required for expression of Shh by facial ectoderm. (A) Diagram of a dorsal view of a St. 9 embryo illustrating the location of the
first arch, second arch, and third arch neural crest populations (purple) while they are in the neural tube (blue). (B) Diagram illustrating the portion of the
dorsal neural tube that was removed to ablate the frontonasal and first arch neural crest precursors. (C) Normal embryo at St. 20 illustrating the relationship
among the nasal pit (np), the eye (ey), the maxillary process (mx), the mandibular process (ma), and the hyoid arch (hy). (D) After removing the anterior
neural folds, the face has failed to undergo mediolateral expansion, the eyes are malpositioned, and the FNP has not begun outgrowth at St. 20. (E) Section
through the midline of a St. 20 embryo demonstrating the presence of Shh transcripts in the telencephalon (te), diencephalon (di), frontonasal ectoderm (fe),
and pharyngeal endoderm (pe). (F) After the ablation of neural crest precursors at St. 9, Shh expression in the frontonasal ectoderm is not initiated at St. 20.
(G) At this stage, Fgf8 transcripts are present in the telencephalon and in frontonasal ectoderm, where it forms a boundary with Shh-expressing ectoderm. (H)
Fgf8 expression is unaltered by neural crest ablation. (I) Normally, BarX1 transcripts are detected in the frontonasal ectoderm that expresses Shh, and (J) this
domain is unaffected by neural crest ablation. (K) Embryos developing to St. 22 after neural fold removal exhibit severe craniofacial defects. (L) Sections
(frontal) through embryos indicate the presence of a large amount of mesenchymal cells in the FNP of these embryos, and in situ hybridization reveals that
Shh transcripts (arrow) are present in the facial ectoderm by St. 22. (M) At St. 20, Shh transcripts (red) are detectable in the ectoderm. (N) High magnification
of the area that is boxed in panel M demonstrating that CFSE-labeled cells (arrows) are located within the mesenchyme of the frontonasal process of embryos
after removal of the dorsal nueral tube. (O) At St. 18, Shh transcripts are only detected in areas adjacent to the mesenchyme (coronal section). (P) High
magnification of the boxed area in panel O illustrates that mesenchymal cells do not occupy the midline of the frontonasal process and are restricted to lateral
regions. Some of these cells are labeled with CFSE, indicating that they were derived form the neural tube. or, optic recess; fb, forebrain; rp, Rathke’s pouch.
Scale bars: E–J: 500 Am, K: 2 mm, L–P: 200 Am.
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Shh antibody at St. 10, then implanted a Shh-N soaked bead
into the frontonasal mesenchyme at St. 19. Although weattempted to implant beads at earlier time points, there is
insufficient space between the forebrain neuroectoderm and
the facial ectoderm to hold the bead in position (the beads
R.S. Marcucio et al. / Developmental Biology 284 (2005) 48–6154were consistently expelled from the embryo or ended up
within the lumen of the neural tube). When initially placed,
the beads were in direct contact with the surface ectoderm.
Over the intervening 24 h, neural crest cells proliferated
around the bead and displaced it a short distance (ca. 50 Am)
from the facial ectoderm (Fig. 4B). Even though the Shh-N
beads were bioactive, as shown by the strong induction of
Ptc and Gli1 in cells around the bead, we did not detect Shh
induction in facial ectoderm (n = 10; Figs. 4A–F). When
considered together with the neural crest extirpation experi-
ments, these results suggested that Shh does not directly up-
regulate Shh expression in the frontonasal ectoderm. Rather,
the data imply that Shh from the forebrain may induce an
intermediate signal, perhaps within the forebrain neuroecto-
derm itself, and that this unknown signal is then responsible
for the induction of Shh in facial ectoderm. We also
attempted to restore Shh expression in facial ectoderm by
placing beads soaked in Fgf2 into the mesenchyme at St. 19
and examining Shh expression 24 h later. However, these
experiments also failed to reveal an up-regulation of Shh in
the facial ectoderm (data not shown).Fig. 4. Replacement of Shh does not rescue the molecular alterations
resulting from blocking Shh signaling within the forebrain. (A) Seventy-
two hours after the injection of hybridoma cells into the neural, and 24 h
after placing a PBS/BSA soaked bead (not visible in this section) into the
frontonasal primordium (St. 20–22), in situ hybridization reveals that Shh
expression (red) is restricted to the diencephalon (di) and is absent from the
facial ectoderm. (B) Placing a bead soaked in Shh-N protein (dotted circle)
does not restore the expression of Shh in the facial ectoderm. (C) Ptc
transcripts (pink) are barely detectable in embryos ‘‘rescued’’ with PBS/
BSA soaked beads, but (D) after the application of Shh-N soaked beads,
Ptc transcripts are readily detectable in the mesenchyme and ectoderm
adjacent to the bead. Likewise, (E) Gli1 (yellow) transcripts are not
abundant in the presence of the PBS/BSA bead, but (F) are up-regulated in
tissues adjacent to the Shh-N soaked bead. te, telencephalon; rp, Rathke’s
pouch; ma, mandible. Scale bar: 200 Am.Disrupting Shh expressed by the diencephalon leads to
defects in the telencephalon
Shh signaling establishes the ventral identity of the
neural tube (Ericson et al., 1995a), and as expected, we
found that the loss of Shh in the telencephalon caused dorsal
genes to be expanded into ventral domains. For example,
Dlx2 is expressed in the basal telencephalon in a domain
that overlaps with Shh, and in the optic recess (n = 6/6, Fig.
5A). After 5E1 inhibition of Shh signaling, Dlx2 expression
was only detected in a small domain within the floor of the
telencephalon (n = 6/6, Fig. 5B). Shh normally restricts the
expression ofPax6 to dorsal regions of the telencephalon (n =
6/6, Fig. 5C). After the inhibition of Shh signaling, Pax6
expression expanded throughout the entire ventral telen-
cephalon (n = 6/6, Fig. 5D). We also assessed the separation
of the forebrain into telencephalic and diencephalic domains
through the analysis of Nkx2.1 expression. In control
embryos, Nkx2.1 in the diencephalon and Nkx2.1 in the
telencephalon were separated by an intervening Nkx2.1-
negative domain in the optic recess (n = 6/6, Fig. 5E). After
perturbing Shh signaling within the forebrain, Nkx2.1
expression extended as a single, continuous domain
throughout the ventral forebrain and the development of
the optic recess appeared to be arrested (n = 6/6, Fig. 5F).
Not all forebrain gene expression patterns were changed.
Otx2 expression is independent of Shh signaling (Gunhaga et
al., 2000), and we found that the pattern of Otx2 was
unaltered by the injection of 5E1-expressing cells (n = 6/6,
Fig. 5G control, compared to H). Thus, we could conclude
that the effects of blocking Shh signaling from the neuroec-
todermwere specific and not due to a generalized loss of gene
expression that followed the onset of apoptosis.
The changes we had noted in the molecular landscape of
the forebrain neuroectoderm were accompanied by altera-
tions in gene expression in the face. For instance, Pax6
expression is normally repressed by Shh (Macdonald et al.,
1995; Stoykova et al., 2000). We found that the loss of Shh
in facial ectoderm was accompanied by a persistence of Pax6
in this region (n = 6/6, Fig. 5D, treated, compared to control,
C). Collectively, these data show that 5E1 treatment caused
ventral neuroectoderm to assume dorsal characteristics.
Loss of telencephalic Shh signaling causes middle and
upper face defects
Losing the telencephalic and frontonasal ectodermal
domains of Shh had a profound impact on mediolateral
expansion of the frontonasal prominence. This change was
readily apparent within 48 h of treatment (n = 12, St. 18–
20, Figs. 6A–D) and became exacerbated with time (n = 7,
72 h, St. 20–24, Figs. 6E–H). As a result, the maxillary
processes converged toward the midline, and the eyes,
which already exhibited microphthalmia, were rotated
ventrally. By 96 h (n = 4, St. 27–29), the craniofacial
malformations outlined above were much more severe. By
Fig. 5. The expression of forebrain markers are differentially affected by Shh
inhibition. (A) In sagittal sections through the midline of embryos exposed
to a hybridoma cell line producing a control antibody, Dlx2 expression
appears normal.Dlx2 (orange) transcripts are observed in the neuroectoderm
(ne) of the ventral telencephalon in control embryos, and (B) after 5E1
treatment,Dlx2 transcripts occupied a smaller domain within the telencepha-
lon. (C) The expression of Pax6 (yellow) is restricted to the dorsal
telencephalon and Rathke’s pouch by St. 22 and is absent from facial
ectoderm that expresses Shh (arrow). (D) After 5E1 treatment, Pax6
transcripts were detected throughout the dorsal and ventral telencephalon
and ectopically in the facial ectoderm (arrow). (E) Nkx2.1 is expressed
throughout the floor of the telencephalon (te) and diencephalon (di), except
for the optic recess (or). (F) After Shh inhibition within the forebrain, a
single Nkx2.1 expression domain spanned the telencephalon and dienceph-
alon uninterrupted by the optic recess. (G) In control embryos, Otx2 is
expressed throughout the floor of the telencephalon and the posterior limit of
the hypothalamus, and (H) in treated embryos, Otx2 expression is unaltered.
ma, mandible; rp, Rathke’s pouch. Scale bar: 200 Am.
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generalized defects in the central nervous system, such as
micropthalmia, along with dysplasias of the middle and
upper face (n = 12, Figs. 7A, B), while embryos injected
with control hybridoma cells showed no discernable
alterations in morphology (n = 12).
We examined the control and treated embryos at St. 40 in
order to more precisely define how Shh inhibition in the
forebrain affected facial skeletogenesis. While no obvious
abnormalities were evident in the mandible, the nasal
capsule, or the nasal bone (n = 12, Figs. 7C, D), we found
malformations in the distal portions of the upper beak (n =12, Figs. 7C, D). The premaxilla, which normally extends
beyond the nasal capsule and forms the lateral, ventral, and
dorsal components of the tip of the upper beak, did not
extend beyond the nasal capsule in treated embryos.
Furthermore, the prenasal cartilage, which normally extends
rostrally from the inner orbital septum, was absent (Figs.
7C–F). In the absence of the prenasal cartilage, the
normally paired primordia of the premaxilla formed as a
single fused element in the midline of the distal part of the
upper beak (Figs. 7G, H). Elements derived from the
maxillary processes were also altered. The paired maxillary
bones were fused medially and were smaller than normal.
Similarly, the palatine bones were shorter and were located
more medially (Figs. 7C–F).
While all of these skeletal elements exhibited changes
in position and size, their relationships to one another
were unaltered by Shh inhibition. The prenasal process of
the premaxilla still extended over the dorsal midline of
the nasal capsule, and caudally, the premaxillae articulat-
ed with the maxillae. Likewise, the caudal part of the
maxillae articulated with the palatine and frontal bones
(Figs. 7C–F). These observations indicated that perturb-
ing Shh signaling within the forebrain disturbed pattern-
ing and growth of individual skeletal elements but did
not disrupt patterning of the facial skeleton as a whole,
nor did it irreversibly alter the program of skeletal tissue
differentiation.
We next wanted to determine whether different cell
concentrations could elicit variable molecular outcomes and
whether these differences would translate into variable
phenotypic responses. We concentrated approximately 4 
106 cells and established three different doses. For the
highest dose, we did not dilute the initial cell pellet. For the
medium dose, we re-suspended the cells with an equal
volume of culture medium. For the lowest dose, we diluted a
portion of the middle dose with an equivalent volume of
culture medium. The neural tube was then filled as before
and the expression of Shh was examined by whole mount in
situ hybridization at St. 22. The expression of Shh in the
frontonasal ectoderm was reduced in a ‘‘dose-dependent’’
manner. For example, in embryos injected with the low dose
of cells, Shh expression was evident in 4/6 embryos; 3/6
embryos injected with the middle dose exhibited Shh
expression; while Shh transcripts were only detected in 1/6
embryos injected with the high dose. These data correlated
with the extent to which the length of the upper beak was
reduced. At the two lower doses, the upper beak was
reduced in length but did extend slightly beyond the nasal
capsule (low dose, n = 3/3, medium dose, n = 3/3, not
shown). In contrast, at the highest dose, the upper beak did
not project beyond the nasal capsule (n = 3/3, not shown).
Thus, the molecular and phenotypic changes depended
directly on the concentration of the 5E1 cells that were
injected into the lumen of the neural tube.
The absence of the prenasal cartilage and the medial
location of elements that are normally found in more lateral
Fig. 6. Progression of the craniofacial phenotype after Shh inhibition. Forty-eight hours after treatment (A, C), control embryos reach St. 18–20. There are no
indications of gross morphological disruptions to the craniofacial complex. The eyes (ey) are prominent and the retina is pigmented. The telencephalon (te) is
divided into right and left halves, and the maxillary (mx), mandibular (ma), and hyoid (hy) arches are apparent, and the nasal pits (np) are widely spaced (dotted
bracket). (B, D) Treated embryos also reach St. 18–20 by 48 h after the injection of 5E1 cells; embryos exhibit marked morphological alterations of the
craniofacial complex. The eyes are reduced in size. The telencephalon is divided into right and left halves, but they appear smaller than the controls. The nasal
pits are present and deepening, but they are close together (bracket). The maxillary processes converge toward the midline and the eyes are rotating ventrally,
while the mandibular and hyoid arches are unaffected. (D) In the lateral view, the craniofacial complex in treated embryos appears blunt. The entire frontonasal
and maxillary primordia appear shorter than (C) the controls. Within 72 h of treatment, normal, (E, G) control, and (F, H) treated embryos reach St. 20–24. (E)
In control embryos, the eyes have enlarged and the facial primordia are well defined. (F) By 72 h, the morphological changes present at 48 h have become more
pronounced. (G) Lateral view of the control embryo showing that the maxillary process extends past the anterior edge of the eye. (H) Lateral view of treated
embryo indicating that the maxillary process extends beyond the anterior edge of the eye, but the eye is reduced in size. The entire frontonasal primordium
appears blunted compared to control embryos. di, diencephalon; me, mesencephalon. Scale bars: 0.5 mm.
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genes that exhibit distinctive mediolateral expression
domains were altered by Shh inhibition in the forebrain.
BarX1 is expressed in the ectoderm covering the FNP, and
in the mesenchyme of the maxillary process (Barlow et al.,
1999), Msx1 is expressed in the lateral mesenchyme of the
FNP (Lee et al., 2001), and AP2 is expressed uniformly
throughout the mesenchyme and ectoderm of the FNP (Shen
et al., 1997). Therefore, any changes in the expression
patterns of these genes may indicate that the medio-lateral
axis of the middle and upper face has been perturbed. We
examined the expression of these genes at 72 h after
treatment (approximately St. 20–24) but failed to detect
alterations in the spatial domains of AP2, BarX1, and Msx1
(Fig. 8). This may be because the genes analyzed are not
definitive markers of the mediolateral axis, or because when
gene expression levels change slightly, these alterations are
sometimes difficult to detect by in situ hybridization.
Even though our initial molecular analyses indirectly
suggested that cells were not dying as a result of the loss of
Shh signaling, we directly tested whether increased
programmed cell death was responsible for the phenotypicalterations. After 24 h, we found TUNEL-positive cells in
nerve tracts located dorsal and caudal to the eyes; however,
no cell death was evident in the frontonasal prominence of
normal (Fig. 9B, untreated, n = 4), control (Fig. 9C, 40-1A-
injected, n = 4), and 5E1-treated embryos (Fig. 9D). At 48
h after treatment, no alterations in the pattern of programmed
cell death were apparent and mesenchymal cells located in
the frontonasal prominence appeared normal. Additionally,
we examined embryos for evidence of apoptosis after Shh
expression should have begun in the facial ectoderm at St. 20
(Figs. 9E, F, n = 4) and at St. 25 (data not shown, n = 4).
Again, we observed minimal cell death in the mesenchymal
tissues located between the forebrain and the surface
ectoderm. This data is consistent with other work from our
laboratory (Cordero et al., 2004). Further, other investigators
have demonstrated that the injection of 5E1 cells into the
forebrain does not lead to apoptosis of neural crest cells, but
injecting 5E1 cells into the mesenchyme outside of the brain
does cause massive cell death within the mandibular neural
crest population (Ahlgren and Bronner-Fraser, 1999).
Since we did not observe massive cell death, we wanted
to determine whether the proliferation of neural crest and
Fig. 7. The inhibition of Shh signaling in the neuroectoderm, beginning at
St. 10, results in a truncation of the upper beak by St. 40. (A) Injection of
hybridoma cells that express an anti-h-galactosidase antibody into the
neural tube does not alter the morphology of the face by 15 days of
development (approximately St. 41). (B) In contrast, the injection of
hybridoma cells expressing the anti-Shh antibody leads to anophthalmia
and truncations of the distal part of the upper beak. The nasal capsule
appears relatively unaffected (asterisk). (C) Dorsal view of the distal tip of
the upper beak after staining with Alcian Blue (cartilage) and Alizarin Red
(bone). The premaxillary bone (pmx) is located at the distal tip of the beak
and two prenasal processes extend (arrows) proximally over the nasal
capsule (nc). (D) After Shh inhibition in the forebrain, the premaxilla does
not extend beyond the nasal capsule and is located medially. The prenasal
processes (arrows) are still present and extend over the nasal capsule, and
the nasal bone (nb) articulates normally with the premaxilla. (E) Ventral
view of the control embryos illustrating that the premaxillary bone forms
the ventral surface of the distal tip of the upper beak. Proximally, the
premaxillary bone articulates with the maxillary bone (mx). The jugal bar
(ju) forms the lateral aspects of the upper beak while the palatine (pt) bones
are located medially. (F) After Shh inhibition, the maxillary bones are fused
medially and the palatine bones are shorter and are located more medially,
indicating that the mediolateral axis of the upper beak has been reduced.
(G) The premaxillary bones form as paired bones that are separated by the
prenasal cartilage (pnc) and are evident as bony masses (dotted lines) by
day 10 of development (approximately St. 36). (H) After Shh inhibition
within the forebrain, the prenasal cartilage is absent and the premaxillary
bone is evident as a single, medial bony mass (arrow). Scale bars: 2 mm.
Fig. 8. Mediolateral gene expression is unaltered by Shh inhibition. (A)
Diagram of a sagittal section through the midline of a St. 20 embryo
illustrating the distal location of the section plane in panels B–E. (B) Ap2
transcripts in the distal frontonasal primordium are found throughout the
mesenchyme and the medial ectoderm. They are not found in the ectoderm
of the nasal pits (np). (C) This same pattern is observed after Shh
inhibition in the forebrain. (D) Msx1 transcripts have a similar distribution,
except that in the mesenchyme, they are restricted to cells immediately
adjacent to the ectoderm. (E) Again, this pattern is not altered by 5E1
treatment. (F) Diagram illustrating the proximal location of the section
plane in panels G–J. (G) In proximal locations, Ap2 transcripts are found
in the mesenchyme of maxillary processes (mx) and midline of the
frontonasal primordium, as well as in the ectoderm covering these
primordia. (H) Section through a 5E1-treated embryo illustrating that
Ap2 expression is indistinguishable from the control embryos. (I)
Proximally, in normal and (J) treated embryos, Msx1 transcripts are
restricted to the maxillary process mesenchyme. te, telencephalon; di,
diencephalon; ma, mandible. Scale bar: 200 Am.
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down-regulated in the ectoderm in response to our
treatment. To accomplish this, we determined the proportionof BrDU-positive cells in 4 sections in each of 5 treated and
4 control embryos at St. 20 (Figs. 9G, H). Our results
indicate that cell proliferation was significantly (P < 0.05)
Fig. 9. Programmed cell death is unaltered by Shh inhibition but changes in
cell proliferation are evident. (A) Diagram of a sagittal section through the
midline of a St. 20 embryo illustrating the approximate location of the
transverse sections (green dotted line) shown in panels B–D. (B) DNA
fragmentation is evident in the eyes and in mesenchymal cells located above
and behind the eyes (arrows), but the mesenchyme and ectoderm of the
frontonasal process (fnp) exhibit very little programmed cell death. (C) At
24 h after treatment, control (hybridoma cells indicated with an asterisk) and
(D) 5E1-treated embryos exhibit little cell death in the FNP. Mesenchymal
cells above and behind the eyes (arrows) still undergo cell death. (E) A
sagittal section through a normal St. 20 embryo showing very few
mesenchymal cells exhibit signs of apoptosis, and (F) at this stage, no
increased evidence of apoptosis is observed in treated embryos. Three
positive cells are identified (arrows). (G) A higher proportion of mesenchy-
mal and ectodermal cells exhibited BrDU incorporation (dark black nuclei) in
normal embryos compared to (H) 5E1-treated embryos ( P < 0.05). Scale bar:
200 Am.
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compared to controls (53.8%, SD = 8.4). Thus, it appears
that a reduction in cell proliferation within the frontonasal
process contributed to the defects in the development of the
upper beak that we observed.Discussion
In this work, we specifically inhibited Shh signaling from
the forebrain neuroectoderm and examined the resultingchanges within this tissue, and within the facial mesen-
chyme and ectoderm. By blocking Shh signaling within the
forebrain, we disrupted the normal Shh induction sequence
in the forebrain and face. These data suggest that the
expression of Shh in the telencephalon and in the
frontonasal ectoderm is controlled by a Shh-dependent
signaling system operating within the neuroectoderm.
Disrupting this signaling process resulted in a decreased
rate of cell proliferation within the frontonasal prominence,
which eventually resulted in foreshortening of the upper
beak.
A signal relay system operates in the forebrain
In our experiments, the blockade of Shh signaling within
the neural tube led to a series of molecular changes within
the telencephalon. For example, when Nkx2.1 expression
normally begins in the telencephalon, it is continuous with
the Nkx2.1 domain in the diencephalon. This expression
domain becomes segregated into two domains, and shortly
after, Shh expression begins in the telencephalon (Crossley
et al., 2001). After inhibiting Shh signaling in the neural
tube, the Nkx2.1 expression domain did not segregate into
distinct diencephalic and telencephalic domains. The lack of
segregation could have resulted because of the failure of the
optic recess to develop, or could have resulted from a more
fundamental failure of the forebrain to become divided into
distinct territories. In either case, these data indicate that a
Shh-dependent signal system operates within the forebrain.
Shh expressed within the diencephalon controls patterns of
gene expression within the developing telencephalon.
Shh signaling is required for ventral identity within the
forebrain (Ericson et al., 1995b; Fishell, 1997), so we
expected that treated embryos would have an expansion of
dorsal marker genes into ventral areas and a reduction in
ventral forebrain markers. This was borne out by our
observations that Pax6 was expanded, and Dlx2 and Nkx2.1
were reduced, in the ventral forebrain. Dorsalization of the
telencephalon and the expression of Pax6 in ventral
domains that we observed could account for altered
Nkx2.1 expression in the telencephalon since Pax6 sup-
presses Nkx gene expression (Chiang et al., 1996; Ericson et
al., 1997) and regulates dorsal–ventral patterning of the
forebrain by delineating the limits of Nkx2.1 and Shh
expression (Stoykova et al., 2000). The Dlx2 expression
domain was noticeably smaller (Fig. 5), which further
supports the idea that the forebrain has assumed a more
dorsal character. A similar reduction in the Dlx2 expression
domain occurs in the telencephalon of the Shh null mouse
(Rallu et al., 2002), indicating that the initial specification of
the ventral forebrain may be independent of Shh signaling.
In fact, signals from the anterior primitive streak may be
sufficient for the initial specification of ventral identity in
the telencephalon (Gunhaga et al., 2000), which could
account for the small Dlx2 domain and the initial Nkx2.1
expression that we observed.
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face regulates the formation of a signaling center in the
ectoderm
In addition to molecular mis-patterning of forebrain
neuroectoderm, gene expression in the facial ectoderm was
disrupted. Previous work from our lab and of others show
that Shh signaling is vital to the proper development of the
middle and upper face. Ectopic Shh signaling causes
hypertelorism (an increase in the space between the orbits)
and, in some severe cases, facial duplications (Hu and
Helms, 1999). Blocking Shh signaling in the face causes
hypotelorism, facial clefting, and general growth restriction
(Ahlgren and Bronner-Fraser, 1999; Cordero et al., 2004;
Hu and Helms, 1999; Jeong et al., 2004).
Inhibiting Shh signaling disrupts a signaling center in the
face
Shh and Fgf8 form an expression boundary in the
frontonasal ectoderm, and this boundary is present before
the expansion and growth of the frontonasal prominence
begins (Hu et al., 2003). The ectoderm comprising this
boundary, which we have named the Frontonasal Ectoder-
mal Zone (FEZ), constitutes a signaling center that regulates
the proximodistal growth and dorsoventral patterning of the
primordium (Hu et al., 2003). Perturbing Shh signaling in
the forebrain neuroectoderm blocked Shh expression in the
facial ectoderm; hence, a component of the FEZ never
formed. Which aspects of the resulting facial disfigurement
were attributable to forebrain mis-patterning versus those
due to disruption in the FEZ has not been unequivocally
determined. Other experimental models such as zebrafish
may be able to clarify which source of Shh, the forebrain
neuroectoderm or facial ectoderm, is responsible for
skeletogenesis in the frontonasal prominence (J. Eberhart
and C. Kimmel, personal communication).
Forebrain signals direct morphogenesis of the middle and
upper face
Losing Shh signaling from the telencephalon and facial
ectoderm caused a specific facial defect where the fronto-
nasal prominence failed to undergo proximodistal outgrowth
and mediolateral expansion. These morphological defects
were first evident within 48 h after treatment (approximately
St. 20) and later manifested as mid-facial hypoplasia and
premaxillary dysgenesis. We anticipated that these morpho-
logical consequences of perturbing Shh signaling within the
forebrain would be less severe than the cyclopic phenotype
resulting from an earlier and more systemic genetic or
biochemical perturbation of Shh signaling (Chiang et al.,
1996; Cordero et al., 2004; Coventry et al., 1998; Incardona
and Roelink, 2000; Incardona et al., 1998; Keeler, 1975).
Regardless of how Shh signaling was disrupted, or whether
certain craniofacial domains of Shh were intact (as in the5E1 experiments), embryos shared two common features:
the loss of mediolateral expansion of the face and the
absence of proximodistal outgrowth of the frontonasal
prominence. The 5E1-induced malformations were limited
to derivatives of the frontonasal and maxillary prominence
(Fig. 7). These data demonstrate that morphogenesis of the
middle and upper face is heavily influenced by signals
emanating from the forebrain.
The phenotypic similarities in malformations caused by
blocking the ability of neural crest cells to transduce a Shh
signal (Jeong et al., 2004), or by blocking Shh signaling
within the neural tube, were highly informative. For example,
Wnt1-Cre;Smon/c embryos appear to have an intact nasal
capsule and lack distal outgrowth of the frontonasal
prominence which results in a foreshortened snout (Jeong
et al., 2004), and this is consistent with what we observed
after the inhibition of Shh signaling within the neural tube. In
our experiments, we also determined that the Shh induction
sequence was disrupted, and this molecular defect could not
be rescued by restoring Shh signaling. Further, Gli1
expression within the diencephalon could not be restored
by placing the Shh-soaked bead in the adjacent mesenchyme,
presumably because the 5E1 antibody continued to exert an
inhibitory effect. These observations need to be interpreted
cautiously, however, since we were only able to replace Shh
signaling immediately prior to stage 20. Continuous Shh
signaling from the neural tube may be required for the normal
induction of Shh expression in the facial ectoderm, which we
were unable to mimic with our experimental design. In
summary, it seems likely that the phenotypic similarities
arose by preventing neural crest cells from responding to Shh
signals from the facial ectoderm, either directly in the Wnt1-
Cre;Smon/c mice or indirectly in our experiments.
The differences in craniofacial morphology between
5E1-treated chick embryos and Wnt1-Cre;Smon/c mouse
embryos were equally informative. For example, Wnt1-
Cre;Smon/c embryos have smaller frontal bones, absent
distal mandibular skeletal elements, truncated skull bases,
and absent hyoid arch structures; none of these skeletal
elements appeared to be affected in 5E-treated embryos.
Coupled with the fact that frontonasal skeletal defects are
equivalent between the mice and chicks, we conclude that
the forebrain domain of Shh is crucial for the development
of frontonasal and maxillary skeletal elements, but appears
dispensable for the development of the other arches.
Signaling among the forebrain, neural crest, and facial
ectoderm
The onset of Shh expression in the facial ectoderm is a
critical time point during the development of the face, and a
number of lines of indirect evidence suggest that cranial
neural crest act as a conduit through which forebrain Shh
regulates facial Shh expression and, in turn, the mediolateral
and proximodistal patterning of the frontonasal prominence.
First, extirpating the cranial neural crest delays the onset of
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a more precocious population of neural crest cells accel-
erates the onset of Shh expression in the face (Schneider and
Helms, 2003). Third, disturbances in craniofacial morphol-
ogy are not observed until e12.0 in Wnt1-Cre;Smon/c mice
(Jeong et al., 2004), which correlates with the arrival of
neural crest cells in the frontonasal midline (our unpublished
observations). Fourth, recombinant Shh-N cannot induce
Shh expression in facial ectoderm directly (Fig. 4), which
suggests that an intermediate cell type or signal is necessary.
Fifth, Shh-expressing neuroectoderm is in direct contact
with facial ectoderm at St. 9, but Shh expression does not
begin in the facial tissue until neural crest cells arrive,
almost 60 h later (Fig. 1). Collectively, these data lead us to
propose that a Shh-dependent signal is generated in the
forebrain that acts on the neural crest cells, and in turn, the
neural crest cells participate in the induction of Shh in the
facial ectoderm.
Clearly, forebrain and facial development are linked, and
our data provide a new insight into how molecular signaling
in the forebrain regulates the establishment of a signaling
center in the face and thus controls its subsequent morpho-
genesis. A molecular dialogue exists among these tissues,
which is essential for patterned outgrowth of the middle and
upper face. By disrupting this molecular dialogue, we have
created embryos with phenotypes that resemble those
observed in patients with moderate forms of HPE (Cohen
and Sulik, 1992;Muenke, 1994), a severe brain malformation
sequence that has accompanying facial defects. Thus, we can
begin to elucidate the molecular mechanism by which defects
in signaling within the forebrain lead to a wide variety of
craniofacial malformations.Acknowledgments
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